This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EyeGate Pharmaceuticals, Inc.
Drug Names(s): thiolated HA topical drop (0.75%), CHMA-S
JDE-003 is a topical eye-drop containing cross-linked thiolated hyaluronic acid (HA) at a concentration of 0.75%. HA is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints and functions as a cushion and lubricant. One of the chief components of the extracellular matrix, HA also contributes significantly to cell proliferation and migration.
JDE-003 is being developed as an eye drop to be used following corneal injury to accelerate healing by increasing corneal epithelial cell motility and by providing an overall ocular surface environment that is conducive to repair. JDE-003 is an adaptation of a proprietary, already-marketed veterinary product sold by BayerDVM under the Remend brand to treat corneal wounds. Cross-linked thiolated HA at a lower concentration is being developed under the drug name JDE-001.
As JDE-003 is regulated as a drug in the U.S., all information pertaining to U.S. development will be found in this BioMedTracker profile. As JDE-003 is regulated as a device in Europe, all information pertaining to the European development will be found in the JDE-003 MedDeviceTracker profile.
BioTime and Jade Therapeutics
In September 2013, BioTime announced the signing of an exclusive sublicense agreement with Jade Therapeutics. This new agreement supersedes previous sublicense and supply agreements and expands the licensed Field of Use to include certain additional uses, such as the use of BioTimes HyStem hydrogel technology for the delivery of all potential therapeutic molecules to the human eye. Excluded from the licensed Field of Use is the use of the HyStem technology for the delivery of cells with or without any molecules necessary for the therapeutic benefit of those cells, for use in making punctal plugs, for diagnostic and research reagents, and for non-human applications. Jades lead products in pre-clinical development utilize the licensed hydrogel technology to facilitate time-release, topical delivery of recombinant human growth hormone to help heal lesions on the ocular surface, as well as enable local delivery of antibiotics to treat ocular...See full deal structure in Biomedtracker
Partners: BioTime, Inc.
Additional information available to subscribers only: